PPT-The ABCs of AF Goals Bleeding With Warfarin

How Frequent Is Bleeding With NOACs Bleeding Risk HASBLED Bleeding Scores in AF Biomarkers in AF Reasons for and Implications of Elevated GDF15 Level GDF15 in ARISTOTLE GDF15 Strongest Bleeding Marker. Andrew McDonald. Alberts Cellular Therapy. “All bleeding eventually stops”. n. Modified Virchow’s triad. BLEEDING. Blood flow. Size. BP. Vessel wall. Endothelial activation. Collagen disorders. Nicolas Novitzky. The Ideal Oral Anticoagulant. Ideally, an oral anticoagulant would: . Have high . efficacy. in reducing thromboembolic events. Reach . therapeutic levels . within several hours. Oral. Eliot Williams, MD PhD. Division of Hematology & Medical Oncology. History of anticoagulant therapy. 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010. د. حسين محمد جمعة . اختصاصي الامراض الباطنة . البورد العربي . كلية طب الموصل . 2010. Anticoagulant drugs. Anticoagulant drugs can be divided into two categories: oral and . st. century: A practical guide to using newer Agents. Katherine Vogel Anderson, . Pharm.D. ., BCACP. University of Florida Colleges of Pharmacy and Medicine. Disclosures . I have nothing to disclose. Definition of Anticoagulation. Therapeutic interference with the clotting mechanism of the blood . ("blood-thinning") to . prevent or treat thrombosis and embolism.. Indications of Anticoagulant Therapy. , MD, PhD . Monday Morning Conference. Oct 4, 2010. Rivaroxaban. Dabigatran. Classes. Unfractionated. heparin. Direct thrombin inhibitors. Low molecular weight heparins, . fondiparinux. Vitamin K antagonists, Inhibiting clotting factors: II, VII, IX, X. Allyson Sarigianis, Pharm.D.. October 19, 2013. Objectives. Review current practice recommendations for prevention of stroke/systemic embolism in atrial fibrillation. Compare and contrast pharmacology between warfarin and target specific oral anticoagulants (TSOACs). Babak Moini, MD. Veterans Affairs Hospital. Noon Lecture . S. eries. Acknowledgment: . Some of the slides were borrowed from Amanda Miller Phar.D. . Case1. 68 male with . hx. of DM, CHF and prior ischemic CVA admitted for new . June 12, 2009. Internal Medicine Morning Report. Sally Ravanos, MD. MKSAP Question #1. A 51yo woman with chronic low back pain is evaluated for a 2-week history of moderate low back pain radiating down her right leg to her right foot following a paroxysm of sneezing. She has no leg weakness or numbness. She is on no meds, and her medical history is only significant for a hysterectomy.. www.onlinecjc.com. ). .  . If your reuse request qualifies as medical institution internal education, you may reuse the material under the following conditions:. You must cite the Canadian Journal of Cardiology and the Canadian Cardiovascular Society as references.. Christopher Granger, . MD. Sean Pokorney, MD. . Disclosure (Dr. Granger). Research contracts: AstraZeneca, Daiichi, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, Medtronic Foundation, The Medicines Company, and Boehringer . Kourosh. . Sadeghi. Tehran University of medical sciences. New Oral Anticoagulants (NOACs). Available in Iran. NOACs. Clinical Trials. RE-LY Study. 951 . clinical . centers in . 44 . countries, . Non-inferiority trial, 18,113 patients, fixed doses of dabigatran 110 mg or 150 mg twice daily — or, in an un-blinded fashion, adjusted-dose warfarin. . 1 COUMADIN Tablets for oralLactose, starch and magnesium stearate 1 mg: D&C Red No. 6 Barium Lake 2 mg: FD&C Blue No. 2 Aluminum Lake and FD&C Red No. 40 Aluminum Lake 2-1/2 mg: D&C Yellow No. 10